Literature DB >> 19533706

Arene control over thiolate to sulfinate oxidation in albumin by organometallic ruthenium anticancer complexes.

Wenbing Hu1, Qun Luo, Xiaoyan Ma, Kui Wu, Jianan Liu, Yi Chen, Shaoxiang Xiong, Jianping Wang, Peter J Sadler, Fuyi Wang.   

Abstract

Interactions of organometallic ruthenium anticancer complexes [Ru(eta6-arene)Cl(en)][PF6] (arene=p-cymene (1) or biphenyl (2), en=ethylenediamine) with human serum albumin were investigated by means of mass spectrometry combined with trypsin digestion, specific sidechain modifications and computational modelling. Both complexes were shown to bind to surface histidine (His128, His247, His510) and methionine (Met298) residues in human albumin, but only the p-cymene complex can gain entry to the crevice containing the free cysteine thiolate (Cys34) and induce oxidation to sulfinate. The two complexes exhibit a similar coordination preference for histidine and methionine residues on the protein surface. His128 binding is favoured both kinetically and thermodynamically. At 310 K, six days of incubation of recombinant human albumin (rHA) with complex 1 (rHA:Ru 50:250 microM) led to about 18 % ruthenation of His128 in the protein. However, the extent of ruthenation of albumin by complex 2 was less than that by 1, due to the steric hindrance from the biphenyl ligand. These results imply that the arene ligand in the organometallic ruthenium anticancer complexes plays a crucial role in interactions with proteins.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19533706     DOI: 10.1002/chem.200900699

Source DB:  PubMed          Journal:  Chemistry        ISSN: 0947-6539            Impact factor:   5.236


  13 in total

1.  Insights into the binding sites of organometallic ruthenium anticancer compounds on peptides using ultra-high resolution mass spectrometry.

Authors:  Rebecca H Wills; Abraha Habtemariam; Andrea F Lopez-Clavijo; Mark P Barrow; Peter J Sadler; Peter B O'Connor
Journal:  J Am Soc Mass Spectrom       Date:  2014-02-01       Impact factor: 3.109

2.  A quantitative study of the biotransformation of insulin-enhancing VO(2+) compounds.

Authors:  Daniele Sanna; Péter Buglyó; Giovanni Micera; Eugenio Garribba
Journal:  J Biol Inorg Chem       Date:  2010-03-26       Impact factor: 3.358

3.  Competitive binding sites of a ruthenium arene anticancer complex on oligonucleotides studied by mass spectrometry: ladder-sequencing versus top-down.

Authors:  Kui Wu; Wenbing Hu; Qun Luo; Xianchan Li; Shaoxiang Xiong; Peter J Sadler; Fuyi Wang
Journal:  J Am Soc Mass Spectrom       Date:  2013-02-13       Impact factor: 3.109

4.  Mir-375 enhances ruthenium-derived compound Rawq01 induced cell death in human ovarian cancer.

Authors:  Xiaowen Shao; Wenjie Mei; Wenhao Weng; Jinlong Qin; Jianhong Zhou; Jie Liu; Jiajing Cheng
Journal:  Int J Clin Exp Pathol       Date:  2013-05-15

Review 5.  Organometallic anticancer compounds.

Authors:  Gilles Gasser; Ingo Ott; Nils Metzler-Nolte
Journal:  J Med Chem       Date:  2010-11-15       Impact factor: 7.446

6.  Binding mechanisms of half-sandwich Rh(III) and Ru(II) arene complexes on human serum albumin: a comparative study.

Authors:  Orsolya Dömötör; Éva A Enyedy
Journal:  J Biol Inorg Chem       Date:  2019-07-12       Impact factor: 3.358

Review 7.  Advances in MS Based Strategies for Probing Ligand-Target Interactions: Focus on Soft Ionization Mass Spectrometric Techniques.

Authors:  Guilin Chen; Minxia Fan; Ye Liu; Baoqing Sun; Meixian Liu; Jianlin Wu; Na Li; Mingquan Guo
Journal:  Front Chem       Date:  2019-10-23       Impact factor: 5.221

8.  Tridentate 3-Substituted Naphthoquinone Ruthenium Arene Complexes: Synthesis, Characterization, Aqueous Behavior, and Theoretical and Biological Studies.

Authors:  Heiko Geisler; Julia Westermayr; Klaudia Cseh; Dominik Wenisch; Valentin Fuchs; Sophia Harringer; Sarah Plutzar; Natalie Gajic; Michaela Hejl; Michael A Jakupec; Philipp Marquetand; Wolfgang Kandioller
Journal:  Inorg Chem       Date:  2021-06-11       Impact factor: 5.165

9.  Comparing the suitability of autodock, gold and glide for the docking and predicting the possible targets of Ru(II)-based complexes as anticancer agents.

Authors:  Adebayo A Adeniyi; Peter A Ajibade
Journal:  Molecules       Date:  2013-03-25       Impact factor: 4.411

10.  The Anticancer Activities of Some Nitrogen Donor Ligands Containing bis-Pyrazole, Bipyridine, and Phenanthroline Moiety Using Docking Methods.

Authors:  Adebayo A Adeniyi; Peter A Ajibade
Journal:  Bioinorg Chem Appl       Date:  2018-06-04       Impact factor: 7.778

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.